Polaris Pharmaceuticals
Soneprasith "Ham" Phonephaly has years of experience in the pharmaceutical industry. Soneprasith "Ham" started their career as a Lab Assistant at Agouron Pharmaceuticals, Inc. in 1998, where they worked in the Department of Molecular Biology. Ham then joined Agouron/Pfizer in 2000 and worked as an Assistant Scientist I in the Fementation Scale-Up department, providing support for large-scale fermentation requests. In 2002, they became an Associate Scientist in the Department of Molecular Biology at Pfizer, where they played a crucial role in early stage drug discovery through structure-based drug design and provided highly purified proteins for various projects. Ham later held roles at Pfizer as a Scientist in the Protein Science and Structural Biology departments, working on projects related to biochemical pharmacology and chemistry. Since 2013, they have been employed at Polaris Pharmaceuticals as a Scientist. The specific responsibilities and duration of their current role are not provided.
Soneprasith "Ham" Phonephaly studied Biology at San Diego State University. No specific start or end years for this education are provided.
Polaris Pharmaceuticals
Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans. Polaris' lead project is ADI-PEG 20, a biotherapeutic agent that is in advanced clinical development for the treatment of hepatocellular carcinoma and metastatic melanoma. Polaris is collaborating with EnzymeRx in the development of Uricase-PEG 20 for the treatment of gout, tumor lysis syndrome, and other diseases related to hyperuricemia. Polaris is also researching and developing other biotherapeutic agents and has a small molecule drug program. The latter utilizes a rational structure-based approach for the design of novel compounds that inhibit the biological function of cancer-related protein targets.